SecBot SecBot

CGEN

COMPUGEN LTD
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. L3· CIK 0001119774 Biotech & Drug Discovery
$2.04 −0.06 (−2.86%)
Nov 16 4:00 PM ET · prev $2.10
Market cap
$200.5M
Micro cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$4.00
+96% · range $4.00–6.00
1 year
+28.3%
from $1.59 · Nov 17
30 days
+3.6%
from $1.97
52-week range
$1.47–3.10
−34% from high · low Dec 29
Avg volume 20D
248.7K
Oct 20 spike 923.3K
Short interest
2.53M
≈2.7% of shares · +0.5%
Days to cover
9.7
at average volume
Insider net
−$118.3K
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Reddit crowd
60°
Warm · 1 mention this week
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $118.3K.

  • InstitutionsBEARISH

    Q3 2026: 2 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.085 → −$0.087 over 90 days.

  • Short sellersSTEADY

    Short interest +0.5% to 2.53M shares. 9.7 days to cover, ≈2.7% of shares.

  • TrendDOWNTREND

    7% below its 50-day average.

  • SocialQUIET

    Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCTRIM158,492$377.2K
GEODE CAPITAL MANAGEMENT, LLCTRIM31,425$74.8K
JANE STREET GROUP, LLCTRIM26,153$62.2K
BLAIR WILLIAM & CO/ILADD22,900$54.5K
ARK Investment Management LLCTRIM786,536$1.7M
MILLENNIUM MANAGEMENT LLCADD262,032$560.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED78,141$167.2K
Quadrature Capital LtdTRIM29,473$63.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy5Buy5Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +96%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 21, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Reddit
Crowd this week 60° Warm 1 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
All social signals and their track records

Insider ledger

Form 4
$0
bought · 0 insiders
$118.3K
sold · 2 insiders
DateInsiderTypeValue
Jul 29, 2026
Kredo Russo Sharon
SVP, Research & Discovery
Jul 29, 2026
AWARD18,000 sh
Jul 29, 2026
Ferre Pierre
Chief Operating Officer
Jul 29, 2026
AWARD70,000 sh
Jul 29, 2026
Ophir Eran
President and CEO
Jul 29, 2026
AWARD200,000 sh
Jul 29, 2026
Livnat Savitzky Kinneret
Director
Jul 29, 2026
AWARD7,500 sh
Jul 29, 2026
ZWEIFACH SANFORD S
Director
Jul 29, 2026
AWARD10,000 sh
Jul 29, 2026
Halevy Gilead
Director
Jul 29, 2026
AWARD7,500 sh
Jul 29, 2026
ZWEIFACH SANFORD S
Director
Jul 29, 2026
AWARD7,500 sh
Jul 29, 2026
Halevy Gilead
Director
Jul 29, 2026
AWARD10,000 sh

Earnings setup

Estimates
−$0.08
EPS estimate, this quarter
−2%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.10–-$0.07+0.0%$3.5M
Next Q-$0.09-$0.09–-$0.07No data$466.7K
Current FY-$0.30-$0.31–-$0.29+9.1%$12.1M
Next FY-$0.35-$0.39–-$0.31+4.5%$7.7M

Short side

FINRA· Oct 30, 2026
2,528,041
shares short
+0.5%
vs prior settlement
9.7
days to cover
≈2.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 Other
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-s
Nov 9, 2026 SEC
Compugen reported Q3 2026 net loss of $5.8M ($0.06 per share), narrower than the $7.0M loss in Q3 2025, on revenue of…
6-K · Impact 4/10
Sep 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC · TRIM
158,492 shares ($377.2K)
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · TRIM
31,425 shares ($74.8K)
Aug 3, 2026 SEC
Compugen Ltd. filed its proxy statement for the 2026 Annual General Meeting via Form 6-K. The meeting will cover the…
6-K · Impact 2/10
Aug 3, 2026 SEC
Compugen reported Q2 2026 results broadly in line with expectations. Revenue rose 35% YoY to $4.8M (H1) driven by…
6-K · Impact 4/10
Jul 29, 2026 Insider
Kredo Russo Sharon was granted 18,000 shares
SVP, Research & Discovery
Jul 29, 2026 Insider
Ferre Pierre was granted 70,000 shares
Chief Operating Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 10, 2026
Press release
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer…
Nov 9, 2026
Earnings result
CGEN Q3 2026 Earnings: EPS $-0.06 (+26.5% vs est)
Nov 3, 2026
Press release
Compugen to Participate in November Investor Conferences
HOLON, Israel, Nov. 3, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in…
Oct 6, 2026
Press release
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in…
Sep 22, 2026
Press release
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer…

SecBot reports

9 filings · 0 bullish · 0 bearish · 9 neutral
All CGEN filing & press-release reports (9)